MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-19-2026
Aeglea BioTherapeutics DSO Ratio 2011-2026 | AGLE
Annual DSO Ratio Aeglea BioTherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 216 | 95.8 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 216 | 95.8 | 156 |
Quarterly DSO Ratio Aeglea BioTherapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 71.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 71.6 | 71.6 | 71.6 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agenus
AGEN
|
4.13 | $ 3.27 | -1.8 % | $ 1.17 M |  USA |
 |
Agios Pharmaceuticals
AGIO
|
47.4 | $ 29.33 | -2.98 % | $ 1.7 B | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Akebia Therapeutics
AKBA
|
62.9 | $ 1.26 | -3.44 % | $ 324 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Alkermes plc
ALKS
|
88.9 | $ 29.32 | -2.61 % | $ 4.83 B |  Irlanda |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
58.1 | $ 330.95 | -0.59 % | $ 43.4 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Altimmune
ALT
|
15.1 K | $ 4.2 | -2.55 % | $ 298 M | USA |
 |
Amgen
AMGN
|
81.2 | $ 387.85 | 0.03 % | $ 209 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
70.9 | $ 20.22 | -0.05 % | $ 945 M | USA |
 |
Amarin Corporation plc
AMRN
|
157 | $ 13.62 | -1.3 % | $ 5.55 B | Irlanda |
 |
AIM ImmunoTech
AIM
|
46 | $ 0.92 | 5.25 % | $ 44.2 M | USA |
 |
AnaptysBio
ANAB
|
95.2 | $ 54.61 | -0.8 % | $ 1.55 B | USA |
 |
Anika Therapeutics
ANIK
|
77.3 | $ 14.44 | 0.53 % | $ 212 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
114 | $ 75.31 | 1.91 % | $ 1.45 B | USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
115 | $ 20.53 | -2.05 % | $ 2.59 B | USA |
 |
Aptorum Group Limited
APM
|
20.6 | $ 0.78 | -0.67 % | $ 4.25 M | China |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptevo Therapeutics
APVO
|
79 | $ 7.28 | -0.55 % | $ 2.01 M | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Aquestive Therapeutics
AQST
|
50.1 | $ 3.99 | -0.15 % | $ 346 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
43.2 | $ 8.11 | -1.44 % | $ 219 M |  Israel |
 |
Ardelyx
ARDX
|
58 | $ 6.32 | -3.54 % | $ 1.52 B | USA |